Hepatocellular carcinoma secondary prevention: Difference between revisions
m Bot: Removing from Primary care |
|||
Line 8: | Line 8: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Needs content]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
Line 21: | Line 20: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] |
Latest revision as of 22:08, 29 July 2020
Hepatocellular carcinoma Microchapters |
Differentiating Hepatocellular carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hepatocellular carcinoma secondary prevention On the Web |
American Roentgen Ray Society Images of Hepatocellular carcinoma secondary prevention |
Risk calculators and risk factors for Hepatocellular carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.
Secondary Prevention
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.[1]
References
- ↑ Colombo M, Donato MF (2005). "Prevention of hepatocellular carcinoma". Semin Liver Dis. 25 (2): 155–61. doi:10.1055/s-2005-871195. PMID 15918144.